Piper Sandler Maintains Overweight on Korro Bio, Maintains $180 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Yasmeen Rahimi has maintained an Overweight rating on Korro Bio (NASDAQ:KRRO) and kept the price target at $180. This reaffirms the firm's positive outlook on the stock.
March 27, 2024 | 4:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler has reaffirmed its Overweight rating on Korro Bio, with a price target of $180, indicating a strong positive outlook on the stock.
The maintenance of an Overweight rating and a high price target by a reputable analyst firm like Piper Sandler usually signals strong confidence in the company's future performance. This can positively influence investor sentiment and potentially lead to an increase in the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100